Literature DB >> 11712284

Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man.

J N Cohn1, F E Tristani, I M Khatri.   

Abstract

The systemic and renal hemodynamic effects of PLV-2 (octapressin) were studied in patients with hypotension or decompensated cirrhosis of the liver. Low doses (0.004 to 0.02 units/min) increased renal blood flow (indicator-dilution technique), reduced renal vascular resistance, and produced a slight increase in arterial pressure and systemic vascular resistance. Higher doses (0.1 to 0.5 units/min) produced a sharp increase in arterial pressure and systemic resistance while renal resistance increased moderately and renal blood flow usually was maintained above control levels. Renal fraction was increased at all dose levels. The increased renal blood flow was accompanied by more rapid intrarenal dye transit time and slight increase in renal extraction ratio of paraaminohippurate suggesting a rise in cortical blood flow. It is concluded that PLV-2 in small doses produces renal vasodilation and in larger doses preferential extra-renal vasoconstriction resulting in redistribution of blood flow to the kidney.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 11712284     DOI: 10.1161/01.cir.38.1.151

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis.

Authors:  K Lenz; H Hörtnagl; W Druml; G Grimm; A Laggner; B Schneeweisz; G Kleinberger
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

2.  The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver.

Authors:  M C Kew; R R Varma; D J Sampson; S Sherlock
Journal:  Gut       Date:  1972-04       Impact factor: 23.059

3.  Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; M Van Kuyk; C Melot; P Lejeune; H Ham; F Vertongen; R Naeije
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

Review 4.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

5.  Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites.

Authors:  Mohammad Minakari; Leila Faiiaz; Mehdi Rowshandel; Ahmad Shavakhi
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.